全文获取类型
收费全文 | 306191篇 |
免费 | 56295篇 |
国内免费 | 7204篇 |
专业分类
耳鼻咽喉 | 3344篇 |
儿科学 | 7894篇 |
妇产科学 | 2826篇 |
基础医学 | 53218篇 |
口腔科学 | 9556篇 |
临床医学 | 28005篇 |
内科学 | 60466篇 |
皮肤病学 | 6730篇 |
神经病学 | 31924篇 |
特种医学 | 9865篇 |
外国民族医学 | 52篇 |
外科学 | 27999篇 |
综合类 | 26892篇 |
现状与发展 | 20篇 |
一般理论 | 14篇 |
预防医学 | 18950篇 |
眼科学 | 3320篇 |
药学 | 40285篇 |
45篇 | |
中国医学 | 9752篇 |
肿瘤学 | 28533篇 |
出版年
2024年 | 417篇 |
2023年 | 3587篇 |
2022年 | 7387篇 |
2021年 | 11536篇 |
2020年 | 13061篇 |
2019年 | 17404篇 |
2018年 | 16572篇 |
2017年 | 17514篇 |
2016年 | 16639篇 |
2015年 | 17813篇 |
2014年 | 21765篇 |
2013年 | 23436篇 |
2012年 | 21090篇 |
2011年 | 23208篇 |
2010年 | 19720篇 |
2009年 | 16250篇 |
2008年 | 16207篇 |
2007年 | 13777篇 |
2006年 | 12519篇 |
2005年 | 11230篇 |
2004年 | 9816篇 |
2003年 | 8874篇 |
2002年 | 7519篇 |
2001年 | 6030篇 |
2000年 | 4443篇 |
1999年 | 3111篇 |
1998年 | 2712篇 |
1997年 | 2524篇 |
1996年 | 2256篇 |
1995年 | 1992篇 |
1994年 | 1812篇 |
1993年 | 1565篇 |
1992年 | 1317篇 |
1991年 | 1254篇 |
1990年 | 1021篇 |
1989年 | 846篇 |
1988年 | 808篇 |
1987年 | 679篇 |
1986年 | 614篇 |
1985年 | 1175篇 |
1984年 | 1256篇 |
1983年 | 898篇 |
1982年 | 972篇 |
1981年 | 814篇 |
1980年 | 759篇 |
1979年 | 647篇 |
1978年 | 509篇 |
1977年 | 445篇 |
1976年 | 533篇 |
1975年 | 442篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
81.
目的探讨维生素D(VitD)联合鱼油对糖尿病前期(PDM)患者糖脂代谢、胰岛β细胞功能的影响。 方法选取PDM患者132例,随机均分为联合组(VitD+鱼油)、VitD组(VitD)和对照组(不干预)。比较各组糖脂代谢、胰岛β细胞功能、炎症反应、血管内皮功能等指标。 结果与干预前比较,干预后联合组甘油三酯降低,白细胞介素-10增高(P<0.05),联合组和VitD组低密度脂蛋白胆固醇、肿瘤坏死因子-α、胰岛素抵抗指数、前列腺素E2、瘦素、抵抗素降低(P<0.05),空腹胰岛素、胰岛β细胞功能指数、脂联素增高(P<0.05),且联合组改善更为明显(P<0.05)。 结论维生素D联合鱼油治疗PDM患者可改善其脂代谢和胰岛功能相关指标,具有一定临床应用价值。 相似文献
82.
《Revista espa?ola de anestesiología y reanimación》2020,67(5):245-252
Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds.In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-CoV-2). Vitamin C, a potent antioxidant, has emerged as a relevant therapy due to its potential benefits when administered intravenous. The potential effect of vitamin C in reducing inflammation in the lungs could play a key role in lung injury caused by coronavirus infection. Another potential effective therapy is ozone: it has been extensively studied and used for many years and its effectiveness has been demonstrated so far in multiples studies. Nevertheless, our goal is not to make an exhaustive review of these therapies but spread the beneficial effects themselves.Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal. 相似文献
83.
84.
《Journal of microbiology, immunology, and infection》2020,53(3):481-484
We reported two cases with community-acquired pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who returned from Wuhan, China in January, 2020. The reported cases highlight non-specific clinical presentations of 2019 novel coronavirus disease (COVID-19) as well as the importance of rapid laboratory-based diagnosis. 相似文献
85.
《Journal of microbiology, immunology, and infection》2020,53(3):425-435
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged in Chinese people in December 2019 and has currently spread worldwide causing the COVID-19 pandemic with more than 150,000 deaths. In order for a SARS-CoV like virus circulating in wild life for a very long time to infect the index case-patient, a number of conditions must be met, foremost among which is the encounter with humans and the presence in homo sapiens of a cellular receptor allowing the virus to bind. Recently it was shown that the SARS-CoV-2 spike protein, binds to the human angiotensin I converting enzyme 2 (ACE2). This molecule is a peptidase expressed at the surface of lung epithelial cells and other tissues, that regulates the renin-angiotensin-aldosterone system. Humans are not equal with respect to the expression levels of the cellular ACE2. Moreover, ACE2 polymorphisms were recently described in human populations. Here we review the most recent evidence that ACE2 expression and/or polymorphism could influence both the susceptibility of people to SARS-CoV-2 infection and the outcome of the COVID-19 disease. Further exploration of the relationship between the virus, the peptidase function of ACE2 and the levels of angiotensin II in SARS-CoV-2 infected patients should help to better understand the pathophysiology of the disease and the multi-organ failures observed in severe COVID-19 cases, particularly heart failure. 相似文献
86.
Cost‐Effectiveness and Cost‐Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study 下载免费PDF全文
Furio Zucco MD Roberta Ciampichini MSc Angelo Lavano MD Amedeo Costantini MD Marisa De Rose MD Paolo Poli MD Gianpaolo Fortini MD Laura Demartini MD Enrico De Simone MD Valentino Menardo MD Piero Cisotto MD Mario Meglio MD Luciana Scalone PhD Lorenzo G. Mantovani DSc 《Neuromodulation》2015,18(4):266-276
87.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis 下载免费PDF全文
88.
89.
90.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献